Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: FLARE

Patient Sexual Orientation & Gender Identity: Do You Need to Know?—Ethics Forum

Nayimisha Balmuri, MD, Jacob Spitznagle, MD, & Karen Onel, MD  |  

A 17-year-old girl presents to the pediatric rheumatology clinic for follow-up of recently diagnosed systemic lupus erythematosus (SLE) characterized by class IV lupus nephritis, photosensitive rash and antiphospholid antibody positivity. She is currently being treated with prednisone, mycophenolate mofetil, and hydroxychloroquine. She is accompanied by her mother, who has been very involved in the patient’s…

How to Leverage Patient-Reported Outcomes to Improve Care for SLE Patients

  |  

A recent study reinforces the growing understanding that the fatigue many SLE patients experience should be considered a lupus symptom. Researchers found that using patient-reported outcomes to identify type 2 symptoms of SLE may improve patient communication, understanding and overall care…

A Transition to 90% Telemedicine: Q&A with Karim Masri, MD

  |  

How are COVID-19 and current restrictions on physical distancing affecting rheumatologists? The Rheumatologist interviewed Karim Masri, MD, to ask how the pandemic has changed the way he and his clinic staff deliver patient care, and how these unprecedented times affect patients, staff and life outside the office. Dr. Masri is a practicing rheumatologist at Bon…

Old Drug, New Interest: COVID-19 Spurs Hydroxychloroquine Supply Concerns for Rheumatic Disease Patients

  |  

After a study investigated if hydroxycholoroquine (HCQ) benefits COVID-19 patients, the drug—used to treat SLE and RA patients—began running out in pharmacies around the U.S. ACR leaders have asked the FDA to increase monitoring of the HCQ supply…

Key Studies Highlighted: 2 Industry Veterans Discuss Their Favorite Annual Meeting Abstracts

  |  

ATLANTA—With more than 3,000 abstracts from 103 countries presented at the 2019 ACR/ARP Annual Meeting in November, it was impossible for attendees to view them all. However, two ACR/ARP veterans—Arthur Kavanaugh, MD, from the University of California, San Diego, and John Cush, MD, from UT Southwestern Medical School, Dallas—chose to tackle the nearly impossible task and…

FDA Update: New Drug Approvals, New & Expanded Indications, & More

  |  

ATLANTA—New drug approvals, new and expanded drug indications, and important safety and other updates relevant for rheumatologists were presented by three physicians from the U.S. Food & Drug Administration (FDA) on Nov. 11 at the 2019 ACR/ARP Annual Meeting. New JAK Inhibitor Approved for RA On Aug. 16, 2019, the FDA approved upadacitinib (Rinvoq), an…

The ACR Introduces a New Reproductive Health Guideline

  |  

Reproductive health can be a concern for patients with rheumatic diseases, and practitioners in both rheumatology and obstetrics/gynecology often work closely together. The 2020 ACR Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases, new clinical recommendations developed by an ACR-convened group for pregnant women, post-menopausal women, lactating women, and women and…